Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice

Breast Cancer Research and Treatment

Volumn 59, Issue 3, 2000, Pages 255-262

  Kahán, Zsuzsanna ^a,b   Nagy, Attila ^a,b   Schally, Andrew V ^a,b   Halmos, Gábor ^a,b   Arencibia, José M ^a,b   Groot, Kate ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxic LH RH analog; Estrogen independent breast cancer; LH RH receptors; MDA MB 231 xenografts; Receptor targeted chemotherapy

Indexed keywords

2 PYRROLINODOXORUBICIN; CYTOTOXIC AGENT; DRUG VEHICLE; ESTROGEN; GONADORELIN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE]; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; MANNITOL; MEMBRANE PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MEMBRANE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LEUKOPENIA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DNA PRIMERS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRROLES; RADIOLIGAND ASSAY; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED;

EID: 0034010324     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006352401912     Document Type: Article

References (27)

1. 1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 48: 6-29, 1998
2. 2. Goldhirsch A, Glick JH, Gelber RD, Seen H-J: Meeting high-lights: International Consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90: 1601-1608, 1998
3. 3. Dees CE, Kennedy JM: Recent advances in systemic therapy for breast cancer. Curr Opin Oncol 10: 517-522, 1998
4. 4. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24(S10): S10-3-S10-10, 1997
5. 5. Schally AV, Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endoc 141: 1-14, 1999
6. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137-147, 1989
7. 7. Emons G, Schally AV: The use of luteinizing hormone-releasing hormone agonists and antagonists in gynaecological cancers. Human Reprod Update 9: 1364-1379, 1994
8. 8. Szepesházi K, Schally AV, Nagy A, Halmos G, Groot K: Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anticancer Drugs 8: 974-987, 1997
9. 9. Yano T, Korkut E, Pinski J, Szepesházi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV: Inhibition of growth of MCF-7-MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 21: 35-45, 1992
10. 10. Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K: Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer 85: 2608-2615, 1999
11. 11. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231-233, 1985
12. 12. Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin-releasing hormone (GnRH)binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425-432, 1987
13. 13. Lamharzi N, Halmos G, Armatis P, Schally AV: Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 12: 671-675, 1998
14. 14. Schally AV, Nagy A, Szepesházi K, Pinski J, Halmos G, Armatis P: LH-RH analogs with cytotoxic radicals. In: Filicori M, Flamigni C (eds) Treatment with GnRH Analogs: Controversies and Perspectives. Carnforth, Parthenon, 1996, pp 33-44
15. 15. Nagy A, Schally AV, Armatis P, Szepesházi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth G, Horvath J: Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 93: 7269-7273, 1996
16. 16. Nagy A, Armatis P, Schally AV: High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 93: 2464-2469, 1996
17. 17. Jungwirth A, Schally AV, Nagy A, Pinski J, Groot K, Galvan G, Szepesházi K, Halmos G: Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 10: 877-884, 1997
18. 18. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepesházi K, Groot K, Armatis P: Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 89: 1803-1809, 1997
19. 19. Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 38: 151-158, 1999
20. 20. Halmos G, Nagy A, Lamharzi N, Schally AV: Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers. Cancer Lett 136: 129-136, 1999
21. 21. Munson PJ, Rodbard D: Ligand: A versatile computerized approach for charaeterization of ligand binding systems. Anal Biochem 107: 220-239, 1980
22. 22. Szepesházi K, Schally AV, Nagy A: Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs. Breast Cancer Res Treat 56: 265-274, 1999
23. 23. Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepesházi K, Groot K: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol 180(5): 1095-1103, 1999
24. 24. Szepesházi K, Schally AV, Halmos G, Szoke B, Groot K, Nagy A: Effect of cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res Treat 40: 129-139, 1996
25. 25. Munkarah A, Chuang L, Lotzova E, Cook K, Morris M, Wharton JT: Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions. Gynecol Oncol 55: 211-216, 1994
26. 26. Kaliste-Korhonen E, Tuovinen K, Hänninen O: Interspecies differences in enzymes reacting with organophosphates and their inhibition by paraoxon in vitro. Human Exp Toxicol 15: 972-978, 1996
27. 27. Kovács M, Schally AV, Nagy A, Koppán M, Groot K: Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 94: 1420-1425, 1997